DE69619110T2 - Adenovirale vektoren für die gentherapie - Google Patents

Adenovirale vektoren für die gentherapie

Info

Publication number
DE69619110T2
DE69619110T2 DE69619110T DE69619110T DE69619110T2 DE 69619110 T2 DE69619110 T2 DE 69619110T2 DE 69619110 T DE69619110 T DE 69619110T DE 69619110 T DE69619110 T DE 69619110T DE 69619110 T2 DE69619110 T2 DE 69619110T2
Authority
DE
Germany
Prior art keywords
helper
gene therapy
adenoviral vectors
preparations
adenoviruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69619110T
Other languages
English (en)
Other versions
DE69619110D1 (de
Inventor
Frank L Graham
Martina Anton
Michael A Rudnicki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advec Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69619110D1 publication Critical patent/DE69619110D1/de
Application granted granted Critical
Publication of DE69619110T2 publication Critical patent/DE69619110T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
DE69619110T 1995-06-07 1996-06-07 Adenovirale vektoren für die gentherapie Expired - Lifetime DE69619110T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/473,168 US5919676A (en) 1993-06-24 1995-06-07 Adenoviral vector system comprising Cre-loxP recombination
PCT/CA1996/000375 WO1996040955A1 (en) 1995-06-07 1996-06-07 Adenovirus vectors for gene therapy

Publications (2)

Publication Number Publication Date
DE69619110D1 DE69619110D1 (de) 2002-03-21
DE69619110T2 true DE69619110T2 (de) 2002-07-18

Family

ID=23878471

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69619110T Expired - Lifetime DE69619110T2 (de) 1995-06-07 1996-06-07 Adenovirale vektoren für die gentherapie

Country Status (8)

Country Link
US (2) US5919676A (de)
EP (1) EP0832267B1 (de)
JP (1) JP3492700B2 (de)
AT (1) ATE213022T1 (de)
AU (1) AU724161B2 (de)
CA (1) CA2220997C (de)
DE (1) DE69619110T2 (de)
WO (1) WO1996040955A1 (de)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164782A1 (en) 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US20020146392A1 (en) * 1993-06-24 2002-10-10 Frank L. Graham Helper dependent adenovirus vectors based on site-specific recombinases
US20020136708A1 (en) * 1993-06-24 2002-09-26 Graham Frank L. System for production of helper dependent adenovirus vectors based on use of endonucleases
US6730507B1 (en) 1993-06-24 2004-05-04 Merck & Co., Inc. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
US7045347B2 (en) 1993-06-24 2006-05-16 Advec, Inc. Helper dependent adenovirus vectors based on integrase family site-specific recombinases
US6379943B1 (en) * 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
JP4216350B2 (ja) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター
US6964861B1 (en) 1998-11-13 2005-11-15 Invitrogen Corporation Enhanced in vitro recombinational cloning of using ribosomal proteins
US20060110798A1 (en) * 1995-06-07 2006-05-25 Graham Frank L Cells expressing recombinase useful for adenovirus vector production and control of gene expression
US6720140B1 (en) 1995-06-07 2004-04-13 Invitrogen Corporation Recombinational cloning using engineered recombination sites
NZ312332A (en) 1995-06-07 2000-01-28 Life Technologies Inc Recombinational cloning using engineered recombination sites
US6143557A (en) * 1995-06-07 2000-11-07 Life Technologies, Inc. Recombination cloning using engineered recombination sites
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
ATE278794T1 (de) * 1995-06-15 2004-10-15 Crucell Holland Bv Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
FR2737501B1 (fr) * 1995-07-31 1997-10-24 Transgene Sa Nouveaux virus auxiliaires pour la preparation de vecteurs viraux recombinants
DE19623203A1 (de) * 1995-11-24 1997-05-28 Max Planck Gesellschaft Virusvektor für den Transfer stabiler Episome
US20020193580A1 (en) * 1995-12-15 2002-12-19 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20060088938A1 (en) * 1995-12-15 2006-04-27 Mitchell Lloyd G Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
US20030027250A1 (en) * 1995-12-15 2003-02-06 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
CA2239366A1 (en) * 1996-01-05 1997-07-17 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors
US6228646B1 (en) * 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
US6630346B1 (en) * 1996-06-20 2003-10-07 Merck & Co., Inc. Gene therapy for obesity
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
BR9711844A (pt) 1996-10-01 2000-01-18 Geron Corp Preparação de proteìna isolada, substancialmente pura ou recombinante, proteìna de trt isolada, substancialmente pura ou recombinante protéina de trt isolada, substancialmente pura ou recombinante, protéina de trt isolada ou uma sua variante, ou um seu fragmento, polinucleotìdeo, sintético, substancialmente puro ou recombinante, ácido nucléico isolado, codificando uma proteìna de trt, vetor de expressão, célula transfectada, animal não-humano, ou sua progênie, animal não-humano transgênico, anticorpo ou seu fragmento de ligação, anticorpo, especificamente imunorreativo sob condições imunologicamente reativas, para uma proteìna de trt ou seu fragmento imunogênico, processos de determinar se um composto ou tratamento é um modulador de uma atividade ou expressão de trt, de determinar se um composto de teste é um modulador de uma atividade de trt, de preparar telomerase recombinante, de detectar um produto genético de trt em uma amostra, de detectar a presença de pelo menos uma célula humana positiva de telomerase em uma amostra biológica compreendendo células humanas, de diagnosticar uma condição relacionada com a telomerase em um mamìfero, para aumentar a capacidade proliferativa de uma célula de vertebrado in vitro, para detectar a presença de yuma sequência de polinucleotìdeo codificando pelo menos uma parte de uma trt em uma amostra bilógica, para produzir um polinucleotìdeo, para detectar a expressão ou presença de uma trt em uma amostra biológica, usos de ummpolinucleotìdeo, de um agente que aumenta a expressão ou atividade de uma trt, de um inibidor da expressão ou atividade de telomerase de uma proteìna, variante ou fragmento, composição farmacêutica, polipeptìdeo substancialmente purificado, sequência de polinucleotìdeo isolado, complexo de telomerase, composição, telomerase substancialmente pura, polipeptìdeo de trt isolado, ácido nucléico isolado.
US6475789B1 (en) * 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US5994132A (en) * 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
EP1484409B1 (de) 1996-12-16 2009-04-08 Eisai R&D Management Co., Ltd. DNA-Konstrukt umfassend ein Medikamenten-Resistenzgen und ein fremdes Gen
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US5851808A (en) * 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
WO1998039411A1 (en) * 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US20050013825A1 (en) * 1997-04-18 2005-01-20 Geron Corporation Vaccine containing the catalytic subunit of telomerase for treating cancer
US7413864B2 (en) * 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) * 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
AU9319198A (en) 1997-09-19 1999-04-05 Trustees Of The University Of Pennsylvania, The Methods and vector constructs useful for production of recombinant aav
DE69836092T2 (de) * 1997-10-24 2007-05-10 Invitrogen Corp., Carlsbad Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
US7351578B2 (en) * 1999-12-10 2008-04-01 Invitrogen Corp. Use of multiple recombination sites with unique specificity in recombinational cloning
EP1034266A1 (de) * 1997-11-25 2000-09-13 Princeton University Methode zur herstellung adenoviraler vektoren, entsprechende vektoren und ihre verwendung
DE19807265C2 (de) * 1998-02-20 2000-01-05 Centeon Pharma Gmbh Adenoviraler Transfervektor für den Gentransport einer DNA-Sequenz
US6337200B1 (en) * 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
CN1342206A (zh) 1998-08-28 2002-03-27 杜克大学 在IVa2,100K和/或preterminal protein序列上有缺失的腺病毒
US6303362B1 (en) 1998-11-19 2001-10-16 The Board Of Trustees Of The Leland Stanford Junior University Adenoviral vector and methods for making and using the same
CA2360796A1 (en) * 1999-02-04 2000-08-10 Merck & Co., Inc. Improved helper dependent vector system for gene therapy
WO2000049166A2 (en) * 1999-02-18 2000-08-24 Merck & Co., Inc. Production of helper dependent adenovirus vectors based on use of endonucleases
JP4580106B2 (ja) * 1999-03-02 2010-11-10 ライフ テクノロジーズ コーポレーション 核酸の組換えクローニングにおける使用のための組成物および方法
WO2000052187A2 (en) 1999-03-05 2000-09-08 Merck & Co., Inc. Enhanced system for construction of adenovirus vectors
US20030215423A1 (en) * 1999-04-01 2003-11-20 Merck & Co., Inc. Gene therapy for obesity
DK2345716T3 (en) * 1999-04-06 2015-02-09 Wisconsin Alumni Res Found RECOMBINANT INFLUENZAVIRA FOR VACCINES AND GENTHERAPY
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
AU768836B2 (en) * 1999-04-06 2004-01-08 Advec, Inc. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
NZ519217A (en) 1999-12-10 2004-03-26 Invitrogen Corp Use of multiple recombination sites with unique specificity in recombinational cloning
US6867022B1 (en) 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
US7132277B1 (en) * 2000-01-31 2006-11-07 Merck & Co., Inc. Helper dependent vector system for gene therapy
AU5533601A (en) 2000-04-14 2001-10-30 Wisconsin Alumni Res Found Viruses comprising mutation ion channel protein
ATE346925T1 (de) 2000-05-10 2006-12-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
US7244560B2 (en) * 2000-05-21 2007-07-17 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6716622B2 (en) * 2000-07-18 2004-04-06 Uab Research Foundation Tissue-specific self-inactivating gene therapy vector
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
WO2002020814A1 (en) * 2000-09-08 2002-03-14 The General Hospital Corporation Self-rearranging dna vectors
EP1320620B1 (de) * 2000-09-25 2015-01-21 The Regents Of The University Of Michigan Herstellung viraler vektoren
EP1344536A4 (de) * 2000-11-24 2005-01-19 Chugai Pharmaceutical Co Ltd Verfahren zur regulierung der wirkung des expressionsprodukts eines in einen lebenden körper transferierten gens
US20040126774A1 (en) * 2001-01-08 2004-07-01 Mitchell Lioyd G. Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
CA2442144A1 (en) * 2001-03-26 2002-11-21 The Board Of Trustees Of The Leland Stanford Junior University A helper dependent adenoviral vector system and methods for using the same
CA2444195A1 (en) * 2001-04-19 2002-10-31 Invitrogen Corporation Compositions and methods for recombinational cloning of nucleic acid molecules
EP1451344A4 (de) * 2001-05-21 2005-03-23 Invitrogen Corp Zusammensetzungen und verfahren zur verwendung bei der isolierung von nukleinsäuremolekülen
CA2451957A1 (en) * 2001-06-28 2003-01-09 Phenogene Therapeutiques Inc. Methods, vectors, cell lines and kits for selecting nucleic acids having a desired feature
CA2460157A1 (en) 2001-09-18 2003-03-27 Clontech Laboratories, Inc. Site-specific recombinase based method for producing adenoviral vectors
US20040002060A1 (en) * 2002-01-24 2004-01-01 Novartis Ag Fiber shaft modifications for efficient targeting
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy
DE60315628T2 (de) 2002-04-09 2008-06-05 Sanofi Pasteur Ltd., Toronto Modifizierte cea nucleinsäure und expressionsvektoren
CA2485341A1 (en) * 2002-05-08 2004-06-17 Intronn, Inc. Use of spliceosome mediated rna trans-splicing to confer cell selective replication to adenoviruses
US8304233B2 (en) 2002-06-04 2012-11-06 Poetic Genetics, Llc Methods of unidirectional, site-specific integration into a genome, compositions and kits for practicing the same
EP1546347A1 (de) * 2002-09-27 2005-06-29 PowderJect Research Limited Nukleinsäurekonstrukt zur genexpression
DE60333032D1 (de) * 2002-10-23 2010-07-29 Virxsys Corp Screening-verfahren zur identifizierung wirksamer prä-trans-spleissmoleküle
US20040203133A1 (en) * 2003-01-07 2004-10-14 Anja Ehrhardt Helper dependent adenoviral vector system and methods for using the same
EP1618191A2 (de) 2003-04-23 2006-01-25 Wisconsin Alumni Research Foundation Rekombinante influenza viren, die eine mutation in einem gen, das für eines transmembrane protein kodiert tragen.
EP1644538A4 (de) * 2003-06-26 2006-11-08 Invitrogen Corp Verfahren und zusammensetzungen zum nachweis von promotoraktivität und zur expression von fusionsproteinen
ATE506444T1 (de) * 2003-10-08 2011-05-15 Sanofi Pasteur Ltd Modifizierter cea/b7-vektor
JP2007512838A (ja) 2003-12-01 2007-05-24 インヴィトロジェン コーポレーション 組換え部位を含む核酸分子およびその使用方法
US8053232B2 (en) * 2004-01-23 2011-11-08 Virxsys Corporation Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
EP1716165A4 (de) * 2004-01-23 2008-06-18 Virxsys Corp Expression von apoa-1 und varianten davon unter verwendung des spleissosom-vermittelten rna-trans-spleissens
US20060094110A1 (en) * 2004-07-30 2006-05-04 Mcgarrity Gerard J Use of spliceosome mediated RNA trans-splicing for immunotherapy
US20060134658A1 (en) * 2004-08-09 2006-06-22 Garcia-Blanco Mariano A Use of RNA trans-splicing for generation of interfering RNA molecules
PL2229956T3 (pl) 2004-09-13 2013-09-30 Genzyme Corp Konstrukty multimeryczne
DE102004047492B4 (de) * 2004-09-23 2006-07-20 Jost-Werke Gmbh & Co. Kg Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
JP5053850B2 (ja) * 2004-10-08 2012-10-24 バークシス コーポレーション 抗体遺伝子導入および抗体ポリペプチド産生のためのｒｎａトランススプライシングの使用
US7871795B2 (en) 2004-10-08 2011-01-18 Virxsys Corporation Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
US7968101B2 (en) 2004-11-19 2011-06-28 Wisconsin Alumni Research Foundation Recombinant influenza vectors with tandem transcription units
CA2625262A1 (en) * 2005-10-13 2007-10-04 Bc Cancer Agency Modular genomes for synthetic biology and metabolic engineering
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
PL1988823T3 (pl) 2006-02-09 2019-01-31 Genzyme Corporation Powolne dostarczanie dokomorowe
US9254318B2 (en) 2006-03-31 2016-02-09 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
ES2337973B8 (es) * 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
WO2011056591A1 (en) 2009-10-26 2011-05-12 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
NZ715957A (en) 2012-02-07 2017-08-25 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
US9950057B2 (en) 2013-07-15 2018-04-24 Wisconsin Alumni Research Foundation (Warf) High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
JP6297692B2 (ja) 2013-08-08 2018-03-20 グローバル・バイオ・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｉｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低侵襲処置用クランプデバイスおよびその使用
EP3564379A1 (de) 2013-09-13 2019-11-06 California Institute of Technology Selektive rückgewinnung
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
RU2727672C2 (ru) 2015-12-11 2020-07-22 Калифорния Инститьют Оф Текнолоджи Нацеливающие пептиды для направленной доставки аденоассоциированных вирусов (aav)
WO2017143236A1 (en) 2016-02-19 2017-08-24 Yoshihiro Kawaoka Improved influenza b virus replication for vaccine development
CA3060573A1 (en) 2017-04-21 2018-10-25 Baylor College Of Medicine Oncolytic virotherapy and immunotherapy
WO2020068990A1 (en) 2018-09-26 2020-04-02 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
EP3914295A2 (de) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutationen zur verleihung von genetischer stabilität gegenüber zusätzlichen genen bei grippeviren
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
US20230167460A1 (en) * 2019-10-23 2023-06-01 Genenmed Co., Ltd. Helper plasmid-based gutless adenovirus production system
JP2023517779A (ja) 2020-03-15 2023-04-26 プロテイネア，インコーポレーテッド 昆虫における組換えタンパク質の産生
WO2023017494A1 (en) 2021-08-13 2023-02-16 Triovance Holding Llc A skin substitute composition and methods of producing and using the same
CN114410683B (zh) * 2022-01-12 2023-11-28 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的RIM3-RNAi及其应用
CN114369623B (zh) * 2022-01-12 2023-07-07 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的Synaptotagmin2-RNAi及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4920211A (en) * 1988-01-04 1990-04-24 Vanderbilt University Mutated adenovirus E1A gene for E1A promoter stimulation
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1993019092A1 (fr) * 1992-03-19 1993-09-30 Centre National De La Recherche Scientifique Adenovirus recombinants defectifs exprimant des proteines caracteristiques du virus epstein-barr
ATE404683T1 (de) * 1992-09-25 2008-08-15 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
JP3532566B2 (ja) * 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
JP4216350B2 (ja) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター

Also Published As

Publication number Publication date
CA2220997A1 (en) 1996-12-19
EP0832267A1 (de) 1998-04-01
EP0832267B1 (de) 2002-02-06
AU5889796A (en) 1996-12-30
JP3492700B2 (ja) 2004-02-03
WO1996040955A1 (en) 1996-12-19
US20010041173A1 (en) 2001-11-15
DE69619110D1 (de) 2002-03-21
AU724161B2 (en) 2000-09-14
JPH11506334A (ja) 1999-06-08
ATE213022T1 (de) 2002-02-15
CA2220997C (en) 2007-04-24
US5919676A (en) 1999-07-06

Similar Documents

Publication Publication Date Title
DE69619110T2 (de) Adenovirale vektoren für die gentherapie
BG102612A (en) Complementary adenoviral vector systems and cellular lines
DE69535178D1 (de) Adenoviren-vektor systeme und zelllinien
NO982417D0 (no) Vektorer og fremgangsmÕter for genoverf°ring til celler
PT797676E (pt) Vector adenoviral recombinante e metodos de utilizacao
DK0667912T3 (da) Defekte adenovirusvektorer og anvendelse heraf i genterapi
ATE387492T1 (de) Verfahren und zusammensetzung zur konservierung von adenoviren
DE69535103D1 (de) Rekombinanter adenovirus welcher eine chimäre penton-base aufweist
ATE282434T1 (de) Eine zusammensetzung enthaltend eine detergenz und einen ein tumorsuppressorgen kodierenden, adenoviralen vektor
SG165153A1 (en) Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
EP0710288A4 (de) Adenovirale vektoren für die behandlung der hämophilie
ATE382695T1 (de) Targeting von adenoviren mit hilfe von konformationsbeschränkten peptidmotiven
CY1111931T1 (el) Φορεις αδενοϊων για την αγωγη νοσου
MX9705937A (es) Procedimiento de preparacion de genoma de adenovirus recombinantes.
AU3169495A (en) Gene therapy for restenosis using an adenoviral vector
WO2000049168A3 (en) Helper adenovirus / helper-dependent adenovirus vector system based on site-specific recombinase activity
WO2000012741A3 (fr) Systeme d'expression inductible
ATE342998T1 (de) Replikation -defektive baculoviren expressionssystem
EP1161262A4 (de) AN DER OBERFLÄCHE VON KARZINOMZELLEN LOKALISIERTES COLLIGIN/HsP47
AU1099697A (en) Novel xylanases, genes encoding them, and uses thereof
CA2237059A1 (en) Targeted adenovirus vectors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ADVEC INC., ANCASTER, ONTARIO, CA

8381 Inventor (new situation)

Inventor name: ANTON, MARTINA, 81657 MUENCHEN, DE

Inventor name: GRAHAM, FRANK L., HAMILTON, CA

Inventor name: RUDNICKI, MICHAEL A., OTTAWA, CA